Publications

Selected Peer-Reviewed Publications:

1. Mafuvadze, B., Liang, Y, and Hyder, S. M. (2014) Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor. Oncology Report, in press.  
2. Liang Y, Besch-Williford C, Aebi J.D., Mafuvadze B, Cook M.T., Zou X, and Hyder, S.M. (2014)      Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-  dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer  Research and Treatment, 146:51–62
3. Carroll C, Liang Y, Besch-Williford C, Benakanakere I, and Hyder, S.M. (2013) An anticancer agent  YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor  development. Int. J. Oncology, 42:179-187.
4. Neubauer H, Schneck H, Seeger H, Cahill M. A., Fehm T, Liang Y, Mafuvadze B, Hyder S.M., and  Mueck, A.O. (2013) Overexpression of PGRMC1—possible mechanism for the observed increased  breast cancer risk using norethindrone in hormone therapy. Menopause, 20: 504-510.
5. 5.  Mafuvadze, B., Liang, Y., Besch-Williford, C, Zhang, Xu, and Hyder, S. M. (2012)   Apigenin  Induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft  tumors. Hormones and Cancer, 3:160–171
6. Lo’pez P’erez PR, Liang Y, Sesch-williford CL, Mafuvadze B, and Hyder SM. (2012) Differential  expression of FGF family members in a progesterone-dependent BT-474 human breast cancer  xenograft model.  Histol Histopathol, 27:337-345.
7. McGee A, Mann CS, Liang Y, Hyder SM, Baines CP. (2011) The Mitochondrial Protein C1qbp  Promotes Cell Proliferation, Migration, and Resistance to Cell Death. Cell Cycle, 10:4119-27.
8. Grintery SZ, Liang Y, Huang S-Y, Hyder SM, Zou X. (2011) Oxidosqualene cyclase: a potential  protein target for anticancer therapeutics. Journal of Molecular Graphics and Modeling  29:795-799.
9. Liang Y, Besch-Williford C, Benakanakere I, Thorpe P, and Hyder, S.M. (2011) Targeting mutant  p53 protein and tumor vasculature: An effective combination therapy for advanced breast tumors. Breast Cancer Research and Treatment 125:407-420
10. Liang Y, Benakanakere I, Besch-Williford C, Hyder RS, Ellersieck MR, and Hyder SM. (2010) Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenograft tumors in nude mice.  Menopause: The Journal of the North American Menopause Society 17:1040-1047
11. Hyder SM, Liang Y, Wu J, and Welbern V. (2009) Regulation of thrombospondin-1 by natural and              synthetic progestins in human breast cancer cells.  End Related Cancer 16:8-9-817.
12. Hyder SM, Liang Y, and Wu J. (2009) Estrogen regulation of thrombospondin-1 in human breast cancer cells.  Int. J. Cancer, 125:1045-1053.
13. Liang Y, Besch-Williford C, and Hyder, S.M. (2009) PRIMA-1 inhibits growth of breast cancer  cells by re-activating mutant p53 protein.  Int J Oncol 35:1015-1023.
14. Liang Y, Besch-Williford C, Brekken R.A., and Hyder, S.M. (2007) Progestin-dependent   progression of human breast tumor xenografts: a novel model for evaluating anti-tumor therapeutics.   Cancer Research 67:9929-9936.
15. Liang Y, Besch-Williford C, Benakanakere I, and Hyder, S.M. (2007) Activation of p53 pathway suppresses proliferation of hormone-dependent human breast cancer cells in vitro and in vivo.  Int J Oncol. 31: 777-784.
16. Liang Y, Brekken R.A., and Hyder, S.M (2006) Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti- hormones. End Related Cancer 13: 905-919.
17. Wu J. Liang Y, Zafar N., and Hyder, S.M. (2005) Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone  receptor-B: implications for treatment resistance. Int J Oncol.  Dec; 27, 6:1647-59                                                                                                     
18. Liang Y and Hyder, S. M. (2005) Proliferation of endothelia and tumor epithelial cells by progestin-induced VEGF from human breast cancer cells: Paracrine and Autocrine effects.  Endocrinology 146: 3632-3641
19. Liang Y, Wu J. and Hyder, S. M. (2005) p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.  Journal of Steroid Biochemistry and Molecular  Biology 93: 173-182
20. Liang Y, Eid, A. M, EL Etreby, Lewis R.W., and Kumar, VJ. (2005) Mitochondria from  TRAIL- resistant prostate cancer cells are capable of responding to apoptotic stimuli. Cellular Signaling, 17: 243-251.
21. Uray I. P, Liang, Y, Hyder, S.M. (2004) Estradiol down-regulates CD36 expression in human breast cancer cells. Cancer Letter 207: 101-107
22. Liang Y, Hou M, Kallab A.M., Barrett, J.T., EL Etreby, F., and Schoenlein P.V. (2003)  Induction of anti-proliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: A role for TGFB International Journal of Oncology 23(2): 369-380
23. Liang Y, EL Etreby M.F., Lewis R.W., and Kumar, VJ. (2002) Mifepristone-induced  secretion of Transforming Growth Factor-B1-induced apoptosis in prostate cancer cells. International Journal of Oncology 21: 1259-1267.
24. Sridhar S, Ali A. Afshan, Liang Y, El Etreby M.F, Lewis W.R, and Kumar M. Vijay (2001) Differential expression of members of the Tumor Necrosis Factor a-related Apoptosis-  inducing legend pathway in prostate cancer cells. Cancer Research 61: 7179-7183                
25. El Etreby M.F. Liang Y, Johnson M.H., Lewis R.W. (2000) Antitumor activity of  mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 Prostate Cancer Models in  nude Mice. The Prostate 42: 99-106
26. El Etreby M.F. Liang Y, and Lewis R.W. (2000) Induction of apoptosis by Mifepristone and Tamoxifen in LNCaP human prostate cancer.  The Prostate 43: 31-42
27. El Etreby M.F, Liang Y, Wrenn R.W and Schoenlein P.V. (1998) Additive effect of  mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells.  Breast Cancer Research and Treatment 51: 149-168                                                                         
28. El Etreby M.F. Liang Y. (1998) Effect of 10.antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Research and  Treatment 49: 109-117
29. Mangold KA, Liang Y, Johnson M, Chandler FW, Lennox KW, Lewis RW, Allsbrook WC, and EL Etreby MF. (1998) Enhanced RT-PCR Assay for mRNA Expression of Prostate Specific Antigen and Prostate Specific Membrane Antigen in Peripheral Blood: Is it Reliable? Molecular Urology 2: (1), 29-34
30. Liang Y, Hannan CJ, Chang BK, and Schoenlein PV. (1997) Enhanced potency of  Daunorubicin against multidrug resistant sub line KB-ChR-8-5-11 by a pulsed magnetic field. Anticancer Research 17: 2083-2088
31. Hannan CJ, Liang Y, Allison JD, and Searle JR.(1994)  In vitro cytotoxicity against human  cancer cell lines during Pulsed Magnetic Field exposure.  Anticancer Research 14: 1517-1520                                                                                         
32. Hannan CJ, Liang Y, Allison JD, Pantazis CG and Searle JR. (1994) Chemotherapy of  human carcinoma xenograft during Pulsed Magnetic Field exposure.  Anticancer Research 14:1521-1524                                                                                                               
33. Chang BK, Liang Y, Miller DW, Bergeron RJ, Porter CW and Wang G. (1993) Effects of diethyl  spermine analogues in human bladder cancer cell lines in culture. The Journal of Urology 150: 1293-1297 34.
34. Chang BK, Bergeron RJ, Porter CW and Liang Y. (1992) Antitumor effects of N-alkylated   polyamine analogues in human pancreatic adenocarcinoma models.  Cancer Chemother  Pharmacal. 30: 179-182
35. Chang BK, Bergeron RJ, Porter CW, Vinson TRT, Liang Y, and Libby PR. (1992)  Regulatory an anti-proliferative effects of N-alkylated polyamine analogues in human and  hamster pancreatic adenocarcinoma cell lines.  Cancer Chemother Pharmacal. 30:183-188
36. Liang Y, Wang N and Liu T. (1991) The effects of Fu-O-G on immunological function and  the toxicity on hematopoietic stem cell in mice. Tumor Therapy and Investigation 18: 196
37. Xu Y, Deng G, Liang Y, and Li C. (1991) The antisense C-HA-RAS Oligodeoxynucleotides inhibit the proliferation of the gastrocarcinoma-DNA-transformed rat 3-3 cells and Reduce  the P21 expression of the cells.  Science in China 34(1): 35-41.
38. Liang Y, Wang N and Dong Z. (1990) Rapid and handy colorimetric assay for quantitative  analysis of cytotoxicity and growth inhibitory cancer cells. Journal of Beijing Medical  University 22: 395                                                                                                               
39. Xu Y, Deng G, Li Z, and Liang Y. (1990) the antisense C-Ha-Ras oligodeoxynucleotides  inhibit the proliferation of the gastrocarcinoma-DNA- transformed rat 3-3 cells.  Scanty Sinica (1): 64 -68   
40. Liang Y, Wang N, Li N, Cui J and Dong Z. (1989) The selective cytotoxicity of the  monoclonal antibody conjugated with Mitomycin C against human gastric cancer cells in  vivo and in vitro.  Acta Pharmaceutica Sinica 24(11): 801-806                                                                       
41. Liang Y, Wang N, Huang Q and Liu T. (1989) A new colorimetric method for quantitative  the toxicity of digestive tract caused by anticancer drugs in mice and determination the  toxicity of 5-FU and FU-O-G. Tumor (4): 71
42. Liang Y, Wang N, Huang Q and Liu T. (1988) Antimetastatic and promoting macrophagic effects of an Injection of  Traditional Chinese Medicines in bearing tumor mice. Chinese Journal of Integrated Traditional and Western Medicine, (8) special issue 1.
43. Wang N, Liang Y, Yu G, Ye A, Zhang Y and Yuan W.(1987) A comparative study on the photodynamic effect of several hematoporphyrin derivatives with different components  Physiological Sciences 7(4): 249
44. Liang Y, Wang N, Xu Y and Wang Q.(1986)  Antitumor effects and inhibition of DNA & RNA biosynthesis in tumor cells by a Traditional Chinese Medicine.  Chinese Journal of Integrated Traditional and Western Medicine 6(9): 549-551
45. Wang K and Liang Y. (1986) A fluorescent method for the determination of the  hematoporphyrin derivatives HPD & HPS in biological tissue. Chinese Pharmaceutical  Bulletin 21(2):186
46. Li Y, Wang, N, Kong J, Li W, and Liang Y. (1986) The effect of acupuncture on immuno-functions  of mice bearing different tumors. Journal of Chinese Medicine of ZheJiang 21(8):376-378
47. Wang N, Yu G, Liang Y, Ye A, Zhang Y and Yuan W. (1986) A comparative studies on the  photodynamic effect, photosensitive side action and toxicity of several Chinese-made  photosensitizes.  Acta Pharmaceutica 21(1): 7
48. Liang Y, Wang N, Ye A, Zhang Y and Yuan W. (1985) The effect of hematoporphyr in  derivative HPD on immunological function of mice.  Shanghai Immunology Journal 5(2): 79
49. Wang N, Liang Y and Li W. (1984) The combined effects of Harringtonine and Methotrexate on the hematopoietic and immunological function in mice. Clinical Oncology 1 (1): 53
50. Wang N, Liang Y and Li W. (1984) The effects of coenzyme Q10 on activity of succinate dehydrogenase and the content of cyclic nucleotide in peritoneal macrophages from mice. Journal of Immunology-Shanghai 4(3):160.                      
51. Wang Q, Zhao Y, Zhao M, Lu G, Liang Y and Meng S. (1980) The anticancer effects of  Yadanzi, a Traditional Chinese Medicine and the role of CAMP & CGMP in inhibition  proliferation, differentiation, and reversion of cancer cells.  Journal of the Traditional Chinese Medicine 21(8): 71        

Abstract and Presentation at Professional Meetings

1. Matthew Cook1, Yayun Liang1, Benford Mafuvadze1, Cynthia Besch-Williford2, Salman M. Hyder1  (2014) The Nutraceutical Luteolin Inhibits Progestin-Dependent VEGF Induction in Breast Cancer      Cells and Blocks Tumor Progression in a Xenograft Model. 96th Annual Endocrine Society Meeting,   June 21-24, Chicago, Illinois.
2. Benford Mafuvadze, BVSc, Yayun Liang, and Salman M. Hyder (2014) Oxidosqualene Synthase  Inhibitor Suppresses Transcriptional Activity of Estrogen Receptor-α (ERα) in Human Breast Cancer  Cells. 96th Annual Endocrine Society Meeting, June 21-24, Chicago, Illinois.
3. Yayun Liang1,2, Xiaoqin Zou1,3 , Cynthia Besch-Williford4, Johannes Aebi5 and Salman M Hyder1,2. Synthetic inhibitors of the cholesterol biosynthetic enzyme oxidosqualene cyclase block proliferation  and survival of breast cancer cells (2013) Proceedings of the Annual Meeting of the American   Association for cancer Research, Vol. 54, #871, P211-212, April 6-10, 2013, Washington, DC.
4. Neubauer H, Schneck H, Seeger H, Cahill M. A., Fehm T, Liang Y, Mafuvadze B, Hyder S.M., and  Mueck, A.O. (2012) Membrane-initiated effects of progestogens alone and in combination with estradiol on the proliferation of human breast cancer cells.  94th Annual Endocrine Society Meeting,  June 23-26, Houston, Texas.
5. Mafuvadze B, Liang Y, Besch-williford CL, and Hyder SM (2012) Apigenin block   medroxyprogesterone acetate-dependent progression of BT-474 human breast tumor xenografts by  inducing apoptosis. The Annual Meeting of the American Association for cancer Research, March 31-April 4, Chicago, IL.
6. Mafuvadze B, Liang Y, Besch-williford CL, and Hyder SM (2012) Preventive and therapeutic  potential of Apigenin against progestin-dependent breast cancer. 94th Annual Endocrine Society Meeting, June 23-26, Houston.
7. López FR, Besch-Williford C, Liang Y, Mafuvadze B, and Hyder SM. (2010) Differential  expression of fibroblast growth factor family members in a progestin-dependent BT-474 human  breast cancer cell xenograft model. 92nd Annual Endocrine Society Meeting, San Diego, CA, P2-54.
8. Liang, Y., Benakanakere, I., Hyder, R. S., and 1Hyder, S. M. (2009) Role of Natural and  Synthetic Progestins in the Progression of Human Breast Tumor Xenografts in Nude Mice. 91th Annual Endocrine Society Meeting, Washington, DC, P1-84. 
9. Liang, Y., Benakanakere, I., Hyder, R. S., and 1Hyder, S. M. (2009) Role of Natural and Synthetic Progestins in the Progression of Human Breast Tumor Xenografts in Nude Mice. Midwest breast cancer research symposium, Iowa City, Iowa, Abstract 37.
10. Liang Y, Besch-Williford C, Benakanakere I, Brandt S, Thorpe P, and Hyder, S.M (2009) Targeting mutant p53 protein and tumor vasculature: An effective combination  therapy for advanced breast tumors.  Proceedings of the Annual Meeting of the  American Association for cancer Research, Vol. 50, #2341, 552-553.
11. Liang Y, Besch-Williford C, Benakanakere I, Brandt S, Thorpe P, and Hyder, S.M  (2008) Targeting mutant p53 protein and tumor vasculature: An effective combination  T herapy for advanced breast tumors.  Proceedings of the Annual Meeting of the  American Association for cancer Research, Vol. 49, #2341, 552-553.
12. Liang Y, Besch-Williford C, Benakanakere I, Brandt S, Thorpe P, and Hyder, S.M. (2008)  A novel and effective combination targeting therapy for advanced human breast  tumors. Era of Hope Department of Defense Breast Cancer Research program  Meeting, 2008 Proceedings 124, p18-4.                                                                                                                    
13. Hyder, S.M., Liang, Y, Wu J and Welbern V. (2008) Estrogen regulation of  Thrombospondin-1 in normal and neoplastic mammary cells. Proceedings of the Annual Meeting of the American Association for cancer Research, Vol. 49, #5443, 1293-1294
14. Hyder, S.M., Liang Y, Benakanakere I, and Besch-Williford C. (2008) Suppression of  breast cancer growth by re-activation of endogenous mutant p53 protein by PRIMA-1. Era of Hope Department of Defense Breast Cancer Research program  Meeting, 2008 Proceedings 442, p66-4.               
15. Hyder SM., Brekken RA, and Liang Y (2007) Re-activation of the p53 pathway in mutant  p53 expressing T47-D breast cancer cells suppresses their estrogen-dependent proliferation   and prevents in vivo tumor formation.  89th Annual Endocrine Society Meeting, Toronto, Canada.
16. Liang Y, Besch-Williford C, Benakanakere I, and Hyder, S.M. (2007) Activation of p53       pathway suppresses proliferation of hormone-dependent human breast cancer cells in vitro and in vivo. Proceedings of The 98stAnnual Meeting of the American Association for cancer   Research, Vol. 48
17. Liang Y, Schnell JD and Hyder SM. (2006) Re-activation of mutant p53 by PRIMA-1 suppresses breast tumor growth. Proceedings of the 97th Annual Meeting of the American  Association for cancer Research, Vol. 47, P523, #2215.
18. Liang Y, Brekken RA and Hyder SM. (2006) VEGF induces proliferation of breast cancer  cells via VEGFR2 (flk/kdr) ands inhibits the growth suppressive effects of anti-hormones.  Proceedings of The 97th Annual Meeting of the American  Association for cancer Research,  Vol. 47, P857, #3650.
19. Liang Y, Brekken RA, and Hyder SM. (2006) VEGF is a proliferative and a survival factor  for breast cancer cells expressing VEGFR2 (flk/kdr): implications for anti-hormone  resistance. 88th Annual Endocrine Society Meeting, Boston, MA.  P3-23.                                                       
20. Hyder SM, Liang Y and Besch-Williford C (2006) Suppression of breast tumor growth by  reactivation of p53 pathway in cancer cells. 88th Annual Endocrine Society Meeting, Boston,  MA.  P1-148.
21. Hyder SM and Liang Y. (2005) Progestin-induced VEGF from human breast cancer cells  increases proliferation of endothelial and tumor epithelial cells via paracrine and autocrine  mechanisms. 87th Annual Endocrine Society Meeting, San Diego, CA P2-646
22. Liang Y, Brandt SL, and Hyder SM. (2005) Proliferation of endothelial and tumor epithelial cells by progestin-induced VEGF from human breast cancer cells: paracrine and autocrine effects. Proceedings of the 96th Annual Meeting of the American Association for cancer Research, Vol. 46, P.300, # 1290
23. Wu J, Liang Y, and Hyder SM. (2005) ICI 182,780 exhibits partial progestin-like activity in  human breast cancer cells expressing increased levels of progesterone receptor-B:  implications for anti-hormone resistance. Proceedings of the 96st Annual Meeting of the America Association for cancer Research, Vol. 45, P.383, # 5782.
24. Hyder S.M., Wu J, Brandt S and Liang Y (2004) Interplay between progesterone receptor and  tumor suppressor p53 controls progestin dependent induction of VEGF in breast cancer cells.  86th Annual Endocrine Society Meeting, New Orleans, Abstract p91.
25. Hyder S.M., Liang Y, Wu J, and Stancel G.M. (2004) Sex-steroid regulation of angiogenic  growth factors in breast and uterine cells.  16th Intl Symposium of the J.Steroid Biochemistry and Molecular Biology, Seefeld, Austria, June 2004, Abstract 17-L                                                                
26. Liang Y, Wu J, and Hyder SM. (2004)  Functional p53 blocks progestin-induced VEGF expression   in human breast cancer cells.  16th Intl Symposium of the J.Steroid Biochemistry and  Molecular Biology, Seefeld, Austria, June 2004, Abstract 113-P
27. Liang Y, Wu J, and Hyder SM. (2004) Functional p53 blocks progestin-induced VEGF  expression in human breast cancer cells.  Proceedings of the 95st Annual Meeting of the   America Association for cancer Research, Vol. 45, P.809, # 3505
28. Liang Y and Hyder SM. (2003) Long-term Survival of MCF-cells in vivo without estrogen: A potential model to study hormone dependent angiogenic switch in breast tumors.   Proceedings of the 94th Annual Meeting of the America Association for cancer Research,  Vol. 44, P.134, #5840.                                                                                                                                               
29. Liang Y, Eid A.M, Lewis, R.W., and Kumar VJ. (2002)  Is cytochrome C a limiting factor in  apoptosis in prostate cancer cells?  Proceedings of the 93th Annual Meeting of the American  Association for cancer Research, Vol. 43, P.533,  #2642.
30. Liang Y, Hou M, El Etreby M.F, and Schoenlein  P.V. (2002) Tamoxifen and mifepristone Therapy induced apoptosis of MDA-231 human breast cancer cells following activation of the TGFb1 Proceedings of the 93thth Annual Meeting of the American Association for cancer Research, Vol.43, P. 90, #450
31. Liang Y, Lewis, R.W. El Etreby M.F., and Kumar VJ. (2000)  Induction of apoptosis by  combination therapy of Mifepristone and Tamoxifen on LNCap-C4 human prostate cancer cells. Proceedings of the 91thAnnual Meeting of the American Association for cancer Research, Vol.41, P44, #284.
32. Liang Y, Lewis, R.W. El Etreby M.F. (1999) Antitumor Activity of Mifepristone in theHuman LNCaP, LNCaP-C4, and LNCaP-C4-2 Prostate Cancer Models in nude Mice.  Proceedings of the 1999 University System of Georgia Research Symposium, C-3.
33. Liang Y, Lewis J, Lewis R.W, and EL Etreby M.F. (1998) Effect of the antiprogestin,   mifepristone antiestrogen, tamoxifen and the combination of both on growth inhibition of  human prostate cancer models in nude mice.  Proceedings of the New Research   Approaches in the Prevention and Cure of Prostate Cancer, C-32.                                                         
34. Liang Y and El Etreby, M.F. (1998) Effect of the antiprogestin, mifepristone, antiestrogen,  tamoxifen and the combination of both on growth inhibition of human prostate cancer  models in nude mice.  Proceedings of the 89th Annual Meeting of the American  Association for cancer Research, Vol.39, 12, #78.
35. EL Etreby MF, Liang Y, Schoenlein P, Wrenn R, Lewis J, Ogle T. (1997) Additive antitumor  activity of tamoxifen and antiprogestins in the MCF-7 human breast cancer model.  Proceedings of the 20th Annual Breast Cancer Symposium, San Antonio, TX.
36. Schoenlein PV, Lewis J, Barrett JT, Wilson ID, Liang Y, EL Etreby MF. (1997) Analysis of  tamoxifen-induced chromosomal DNA fragmentation with pulsed field gel electrophoresis. Proceedings of the 88th Annual Meeting of the American Association for cancer Research,  Vol.38, 114, #762.
37. Lewis J, Liang Y, Schoenlein P, Ogle T, Borke J, Sharawy M, Sherry R, EL Etreby MF. (1997) Additive growth inhibitory effect of tamoxifen and mifeprostone on a hormone- responsive human breast cancer cell line. Proceedings of the 88th Annual Meeting of the  American Association for cancer Research, Vol.38, P573, #3843.                                                           
38. Mangold KA, Liang Y, Huey LO, Chandle FW, Lennox K, Lewis R, EL-Etreby F, Allsbrook  Jr WC. (1997) Validity of enhanced RT-PCR assay for PSA and PSM in peripheral  blood: Discordance with demonstrated absence or presence of prostate cancer.  Proceedings of the 88th Annual Meeting of the American Association for cancer Research, Vol.38,  P527, #3531.
39. Liang Y, Lewis J, Schoenlein PV, Ogle T, Borke J, Sharawy M, Sherry R,  El  Etreby  MF. (1997) Steroid receptor-mediated growth inhibitory activity of antiestrogens and  antiprogestins in a hormone-responsive human breast cancer cell line.  Proceedings of the 88th Annual Meeting of the American Association for cancer Research, Vol.38, P572, #3838.
40. Liang Y, Hannan CJ, Chang BK and Schoenlein PV. (1997) Pulsed magnetic field potentiates  Daunorubicin cytotoxicity in MDR KB-ChR-8-5-11 xenograft.   Proceedings of the 88th  Annual Meeting of the American Association for cancer Research, Vol.38, P595, #3994.
41. Hannan CJ, Liang Y, Schoenlein PV, Wrenn RW and Chang BK. (1995) Magnetic  not  electric field inhibition of multidrug resistance.  Proceeding of the86th American Association for  Cancer Research Vol. 36, P345
42. Hannan CJ, Liang Y. (1994) Potentiation of daunorubicin cytotoxicity by a 60 H  magnetic field. Proceedings of the 1994 International Symposium on Charge and Field Effects in Biosystems. 218-222
43. Liang Y, Chang BK, Bergeron RJ and Vinson JRT. (1990)  N-Alkylated polyamine analogues in the therapy of pancreatic adenocarcinoma. First Annual USS Abstracts Session 2, #31.